Assessing Agilent Technologies (A) Valuation After Recent Pullback in an Ongoing Longer-Term Uptrend

Simply Wall St

Agilent Technologies (A) slipped slightly in the latest session, extending its pullback over the past month even though its longer term performance remains positive. Investors are now weighing recent weakness against improving growth fundamentals.

See our latest analysis for Agilent Technologies.

With the share price around $142.87, Agilent’s recent 7 day and 30 day share price declines contrast with a solid 90 day share price return. This suggests momentum has cooled but has not reversed the broader uptrend.

If Agilent’s move has you reassessing healthcare exposure, this could be a good moment to explore other healthcare stocks that might complement your watchlist.

With revenue and earnings still growing and the share price sitting below analyst targets but above some intrinsic estimates, is Agilent quietly undervalued here, or is the market already pricing in its next leg of growth?

Most Popular Narrative Narrative: 15% Undervalued

With Agilent closing at $142.87 against a most popular narrative fair value near $167.57, the story points to meaningful upside if its forecasts land.

Strategic investments in higher margin recurring revenue streams including consumables, software, services, and digital platforms are gaining traction, with CrossLab and services delivering consistent mid single digit growth and high customer satisfaction, indicating further margin expansion and greater earnings stability in future periods.

Read the complete narrative.

Curious how expanding recurring revenue, widening margins, and a richer future earnings multiple all combine to justify that higher value target? The full narrative unpacks the precise growth path, profitability shift, and re rating assumptions driving this upside case.

Result: Fair Value of $167.57 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, elevated tariffs and tighter academic funding could erode margins and dampen instrument demand, challenging the growth assumptions behind this upside case.

Find out about the key risks to this Agilent Technologies narrative.

Another View: Market Ratio Signals Caution

While the narrative fair value points to upside, our price to earnings cross check sends a cooler message. Agilent trades on roughly 31x earnings, cheaper than the Life Sciences industry at about 34x and peers near 35x, but above its fair ratio of 24.9x. That gap suggests valuation risk if sentiment normalizes or growth disappoints, rather than clear cut opportunity.

See what the numbers say about this price — find out in our valuation breakdown.

NYSE:A PE Ratio as at Dec 2025

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Agilent Technologies for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 904 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Build Your Own Agilent Technologies Narrative

If this view does not align with your own, or you prefer digging into the numbers independently, you can craft a full narrative in minutes with Do it your way.

A good starting point is our analysis highlighting 3 key rewards investors are optimistic about regarding Agilent Technologies.

Looking for your next investment move?

Before you move on, lock in an edge by scanning hand picked stock ideas on Simply Wall Street’s Screener so fresh opportunities never slip past you.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Valuation is complex, but we're here to simplify it.

Discover if Agilent Technologies might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com